Vigilant expands executive leadership team
Mr. Stanley joins Vigilant Biosciences as an accomplished commercial executive with more than 25 years of experience in the biopharmaceutical and diagnostics industry. He most recently served as Vice President of Sales and Marketing for Global Diagnostics Business Unit OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company.
Prior to his position at OPKO Health, Inc., Mr. Stanley spent seven years as Chief Commercial Officer at Oncimmune, an oncology company focused on the early detection of cancer. Previously, from 2001 to 2006, Mr. Stanley was Director of Marketing and National Director of Corporate Accounts at Roche Diagnostics.
Mr. Stanley began his career at Abbott Laboratories, and went on to hold a series of positions with increasing responsibility at various diagnostics and biotechnology companies including Chiron and Radiometer before joining Roche Diagnostics in 2001. He received his B.S. from the University of Missouri-Saint Louis.
Mr. Barabe has enjoyed a distinguished career in the life sciences and pharmaceutical industries. He most recently served as Executive Vice President and Chief Financial Officer of Affymetrix, Inc., a pioneer in microarray technology and a leader in genomics analysis. He retired from the position in June 2013.
Previously, from July 2006 until March 2010, he was Senior Vice President and Chief Financial Officer of Human Genome Sciences, Inc. Prior to Human Genome Sciences, Mr. Barabe was with Regent Medical Limited, a U.K.-based, privately owned, surgical supply company, where he was Chief Financial Officer, from 2004 to 2006.
Mr. Barabe began his career at Novartis AG where from 1982 through August 2004 he held a succession of senior executive positions in finance and general management, most recently as the Chief Financial Officer of Sandoz GmbH, the generic pharmaceutical subsidiary of Novartis.
In addition to Vigilant, Mr. Barabe serves on the Board of Directors for Opexa Therapeutics, Inc., a biopharmaceutical company developing personalized immunotherapy for multiple scleroris, and ArQule, Inc., a clinically-staged cancer therapeutic company. ■